Global chipmaker giant NVIDIA kicked off JPM Week with several partnership announcements, most notably a billion dollar ...

The licensing agreement, which includes a big upfront payment of $650 million and milestone payments of up to $4.95 billion, ...

The 2025 American Society of Hematology (ASH) meeting in December presented a clear message: scientific innovation and ...

"Regulatory flexibility must be tailored for cell and gene therapies," commented FDA Commissioner Marty Makary. "These are ...

French newspaper La Lettre said the Paris-based biotech – which is listed on the Nasdaq – has been on Lilly's radar after ...

Madrigal Pharma is reheating a drug for metabolic dysfunction-associated steatohepatitis (MASH) put on ice by Pfizer, hoping ...

The two IPOs, which follow radiopharma specialist Aktis Oncology's filing last week, have investors and industry watchers ...

Their shared dedication reflects a broader mission to bring meaningful change to women’s health, offering hope and tangible ...

For instance, solutions like eWizard flag errors, from missing references to inappropriate images or typos. And when ...

Eight digital health technologies (DHTs) designed to support people with asthma can be used by the NHS in England while additional evidence of their benefits is gathered. That is the conclusion of the ...

Last week will likely be remembered as the one in which pharma frustrations with the UK boiled over. MSD's decision to pull back from a £1 billion ($1.35 billion) investment in the country was bad ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...